{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:44:39Z","timestamp":1792593879160,"version":"4.5.0"},"reference-count":152,"publisher":"MyJove Corporation","issue":"224","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JoVE"],"DOI":"10.3791\/69357","type":"journal-article","created":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T23:01:44Z","timestamp":1759532504000},"source":"Crossref","is-referenced-by-count":1,"title":["Precision Management of Dyslipidemia in Atherosclerosis: Mechanisms, Therapeutic Strategies, and Future Directions"],"prefix":"10.3791","author":[{"given":"Ganyuan","family":"Deng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qun","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maomao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luming","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2098","published-online":{"date-parts":[[2025,10,3]]},"reference":[{"issue":"1","key":"ref1","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/s41467-023-36614-w","type":"journal-article","article-title":"GSDME-mediated pyroptosis promotes the progression and associated inflammation of atherosclerosis","volume":"14","author":"Wei","year":"2023","unstructured":"Wei, Y. et al. GSDME-mediated pyroptosis promotes the progression and associated inflammation of atherosclerosis. Nat Commun. 14 (1), 929 (2023).","journal-title":"Nat Commun"},{"issue":"4","key":"ref2","first-page":"277","type":"journal-article","article-title":"Arteriosclerosis and immunity","volume":"30","author":"Xiao","year":"2022","unstructured":"Xiao, S. J., Zhao, M. Arteriosclerosis and immunity. Chin J Arterioscler. 30 (4), 277-286 (2022).","journal-title":"Chin J Arterioscler"},{"key":"ref3","first-page":"e62933","type":"journal-article","article-title":"Optical coherence tomography based biomechanical fluid-structure interaction analysis of coronary atherosclerosis progression","volume":"179","author":"Carpenter","year":"2022","unstructured":"Carpenter, H. J. et al. Optical coherence tomography based biomechanical fluid-structure interaction analysis of coronary atherosclerosis progression. J Vis Exp. 179, e62933 (2022).","journal-title":"J Vis Exp"},{"issue":"2","key":"ref4","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1161\/CIRCRESAHA.120.315890","type":"journal-article","article-title":"The molecular basis of predicting atherosclerotic cardiovascular disease risk","volume":"128","author":"Nayor","year":"2021","unstructured":"Nayor, M., Brown, K. J., Vasan, R. S. The molecular basis of predicting atherosclerotic cardiovascular disease risk. Circ Res. 128 (2), 287-303 (2021).","journal-title":"Circ Res"},{"key":"ref5","type":"book","article-title":"Summary of China Cardiovascular Health and Disease Report 2022","volume-title":"Chin J Intervent Cardiol","year":"2023","unstructured":"Summary of China Cardiovascular Health and Disease Report 2022. Chin J Intervent Cardiol. 31 (7), 485-508 (2023)."},{"issue":"193","key":"ref6","first-page":"e64983","type":"journal-article","article-title":"Large animal models of cardiovascular disease: From training to translation","author":"B\u00e1ez-D\u00edaz","year":"2023","unstructured":"B\u00e1ez-D\u00edaz, C., Cris\u00f3stomo, V. Large animal models of cardiovascular disease: From training to translation. J Vis Exp. 193, e64983 (2023).","journal-title":"J Vis Exp"},{"issue":"1","key":"ref7","first-page":"119","type":"journal-article","article-title":"Drug literacy status and influencing factors of elderly cardiovascular disease patients in rural Hunan","volume":"20","author":"Li","year":"2023","unstructured":"Li, J. L. et al. Drug literacy status and influencing factors of elderly cardiovascular disease patients in rural Hunan. J Hunan Norm Univ Med Sci. 20 (1), 119-124 (2023).","journal-title":"J Hunan Norm Univ Med Sci"},{"issue":"29","key":"ref8","first-page":"135","type":"journal-article","article-title":"Analysis of health management effect in AS patients","volume":"40","author":"Huang","year":"2024","unstructured":"Huang, Y., Zhao, X. Analysis of health management effect in AS patients. Chin Community Phys. 40 (29), 135-137 (2024).","journal-title":"Chin Community Phys"},{"issue":"12","key":"ref9","first-page":"184","type":"journal-article","article-title":"Research progress on noninvasive molecular imaging of vulnerable plaques in atherosclerosis","volume":"20","author":"Ding","year":"2022","unstructured":"Ding, E. C., Lu, D. Y., Wei, L. J., Shen, J. Research progress on noninvasive molecular imaging of vulnerable plaques in atherosclerosis. Chin J CT MRI. 20 (12), 184-185 (2022).","journal-title":"Chin J CT MRI"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3390\/metabo14050257","type":"journal-article","article-title":"Microbiome-metabolome analysis insight into the effects of the extract of Phyllanthus emblica L. on high-fat diet-induced hyperlipidemia","volume":"14","author":"Wang","year":"2024","unstructured":"Wang, J. et al. Microbiome-metabolome analysis insight into the effects of the extract of Phyllanthus emblica L. on high-fat diet-induced hyperlipidemia. Metabolites. 14, 257 (2024).","journal-title":"Metabolites"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"9420015","DOI":"10.26599\/FMH.2024.9420015","type":"journal-article","article-title":"Identification and mechanism elucidation of medicative diet for food therapy XQCSY in NAFLD prevention: an integrative in silico study","volume":"1","author":"Ren","year":"2024","unstructured":"Ren, C. X. et al. Identification and mechanism elucidation of medicative diet for food therapy XQCSY in NAFLD prevention: an integrative in silico study. Food Med Homol. 1, 9420015 (2024).","journal-title":"Food Med Homol"},{"issue":"139","key":"ref12","first-page":"e58132","type":"journal-article","article-title":"Hydra, a computer-based platform for aiding clinicians in cardiovascular analysis and diagnosis","author":"Ramos","year":"2018","unstructured":"Ramos, L. et al. Hydra, a computer-based platform for aiding clinicians in cardiovascular analysis and diagnosis. J Vis Exp. 139, e58132 (2018).","journal-title":"J Vis Exp"},{"key":"ref13","first-page":"44","type":"journal-article","article-title":"Application of computer-aided drug design in the research of natural anti-tumor drugs","volume":"44","author":"Xu","year":"2023","unstructured":"Xu, D. L., et al. Application of computer-aided drug design in the research of natural anti-tumor drugs. Journal of Ningxia University (Natural Science Edition). 44, 44-52 (2023).","journal-title":"Journal of Ningxia University (Natural Science Edition)"},{"issue":"6","key":"ref14","first-page":"466","type":"journal-article","article-title":"Research progress of liver X receptor in nonalcoholic fatty liver disease","volume":"50","author":"Wang","year":"2024","unstructured":"Wang, L. Q., Li, C. P. Research progress of liver X receptor in nonalcoholic fatty liver disease. Mod Clin Med. 50 (6), 466-470 (2024).","journal-title":"Mod Clin Med"},{"issue":"1","key":"ref15","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1186\/s12951-021-01108-8","type":"journal-article","article-title":"A nanodrug system overexpressed circRNA_0001805 alleviates nonalcoholic fatty liver disease via miR-106a-5p\/miR-320a and ABCA1\/CPT1a axis","volume":"19","author":"Li","year":"2021","unstructured":"Li, J. et al. A nanodrug system overexpressed circRNA_0001805 alleviates nonalcoholic fatty liver disease via miR-106a-5p\/miR-320a and ABCA1\/CPT1a axis. J Nanobiotechnol. 19 (1), 363 (2021).","journal-title":"J Nanobiotechnol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.addr.2020.07.013","type":"journal-article","article-title":"Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention","volume":"159","author":"Butler","year":"2020","unstructured":"Butler, L. M. et al. Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention. Adv Drug Deliv Rev. 159, 245-293 (2020).","journal-title":"Adv Drug Deliv Rev"},{"issue":"3","key":"ref17","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.cmet.2015.03.002","type":"journal-article","article-title":"Uncoupling nuclear receptor LXR and cholesterol metabolism in cancer","volume":"21","author":"Bovenga","year":"2015","unstructured":"Bovenga, F., Sabb\u00e0, C., Moschetta, A. Uncoupling nuclear receptor LXR and cholesterol metabolism in cancer. Cell Metab. 21 (3), 517-526 (2015).","journal-title":"Cell Metab"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"9420003","DOI":"10.26599\/FMH.2024.9420003","type":"journal-article","article-title":"The food and medicinal homological resources benefiting patients with hyperlipidemia: categories, functional components, and mechanisms","volume":"1","author":"Hao","year":"2024","unstructured":"Hao, X. T. et al. The food and medicinal homological resources benefiting patients with hyperlipidemia: categories, functional components, and mechanisms. Food Med Homol. 1, 9420003 (2024).","journal-title":"Food Med Homol"},{"issue":"6","key":"ref19","first-page":"716","type":"journal-article","article-title":"Effect of PPAR\u03b3 on liver fibrosis progression and its ligand drug development","volume":"21","author":"Zhao","year":"2024","unstructured":"Zhao, X. L., Gao, X. Y., Zhang, C. Y., Li, M. Q., Ma, Y. H. Effect of PPAR\u03b3 on liver fibrosis progression and its ligand drug development. Chin J Pharmacovigil. 21 (6), 716-720 (2024).","journal-title":"Chin J Pharmacovigil"},{"issue":"Pt 1","key":"ref20","doi-asserted-by":"crossref","first-page":"136744","DOI":"10.1016\/j.ijbiomac.2024.136744","type":"journal-article","article-title":"Structural characterization of red yeast rice-derived polysaccharide and its promotion of lipid metabolism and gut function in high-fat diet-induced mice","volume":"282","author":"Qi","year":"2024","unstructured":"Qi, L. et al. Structural characterization of red yeast rice-derived polysaccharide and its promotion of lipid metabolism and gut function in high-fat diet-induced mice. Int J Biol Macromol. 282 (Pt 1), 136744 (2024).","journal-title":"Int J Biol Macromol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.ejmech.2019.01.067","type":"journal-article","article-title":"Role of PPAR receptor in different diseases and their ligands: Physiological importance and clinical implications","volume":"166","author":"Mirza","year":"2019","unstructured":"Mirza, A. Z., Althagafi, I. I., Shamshad, H. Role of PPAR receptor in different diseases and their ligands: Physiological importance and clinical implications. Eur J Med Chem. 166, 502-513 (2019).","journal-title":"Eur J Med Chem"},{"issue":"12","key":"ref22","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.3390\/cells8121623","type":"journal-article","article-title":"Vascular PPAR \u03b2\/\u03b4 promotes tumor angiogenesis and progression","volume":"8","author":"Wagner","year":"2019","unstructured":"Wagner, K. D. et al. Vascular PPAR \u03b2\/\u03b4 promotes tumor angiogenesis and progression. Cells. 8 (12), 1623 (2019).","journal-title":"Cells"},{"issue":"9","key":"ref23","first-page":"85","type":"journal-article","article-title":"Research progress on lipid metabolism regulation via SREBPs, PPARs and PCSK9 pathways","volume":"39","author":"Li","year":"2022","unstructured":"Li, L., Li, X., Fang, Y. F., Zhou, Y. K., Ma, S. J. Research progress on lipid metabolism regulation via SREBPs, PPARs and PCSK9 pathways. Inf Tradit Chin Med. 39 (9), 85-89 (2022).","journal-title":"Inf Tradit Chin Med"},{"issue":"6","key":"ref24","first-page":"715","type":"journal-article","article-title":"Research progress of lipid metabolism in glioma","volume":"19","author":"Wang","year":"2022","unstructured":"Wang, K. X., Zhang, S. Y., Ji, H. M., Hu, C. C. Research progress of lipid metabolism in glioma. J Clin Neurosurg. 19 (6), 715-720 (2022).","journal-title":"J Clin Neurosurg"},{"issue":"3","key":"ref25","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41556-018-0270-5","type":"journal-article","article-title":"Extracellular matrix mechanical cues regulate lipid metabolism through Lipin-1 and SREBP","volume":"21","author":"Romani","year":"2019","unstructured":"Romani, P. et al. Extracellular matrix mechanical cues regulate lipid metabolism through Lipin-1 and SREBP. Nat Cell Biol. 21 (3), 338-347 (2019).","journal-title":"Nat Cell Biol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.1007\/s12013-025-01736-z","type":"journal-article","article-title":"SERBP1 (Hero45) is a novel link with ischemic heart disease risk: Associations with coronary arteries occlusion, blood coagulation and lipid profile","volume":"83","author":"Shilenok","year":"2025","unstructured":"Shilenok, V., Kobzeva, K., Bushueva, O. SERBP1 (Hero45) is a novel link with ischemic heart disease risk: Associations with coronary arteries occlusion, blood coagulation and lipid profile. Cell Biochem Biophys. 83, 3557-3569 (2025).","journal-title":"Cell Biochem Biophys"},{"issue":"11","key":"ref27","doi-asserted-by":"crossref","first-page":"6074","DOI":"10.3390\/ijms22116074","type":"journal-article","article-title":"The impact of anthocyanins and iridoids on transcription factors crucial for lipid and cholesterol homeostasis","volume":"22","author":"Danielewski","year":"2021","unstructured":"Danielewski, M. et al. The impact of anthocyanins and iridoids on transcription factors crucial for lipid and cholesterol homeostasis. Int J Mol Sci. 22 (11), 6074 (2021).","journal-title":"Int J Mol Sci"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"105639","DOI":"10.1016\/j.phrs.2021.105639","type":"journal-article","article-title":"Yin-xing-tong-mai decoction attenuates atherosclerosis via activating PPAR\u03b3-LXR\u03b1-ABCA1\/ABCG1 pathway","volume":"169","author":"Zheng","year":"2021","unstructured":"Zheng, S. et al. Yin-xing-tong-mai decoction attenuates atherosclerosis via activating PPAR\u03b3-LXR\u03b1-ABCA1\/ABCG1 pathway. Pharmacol Res. 169, 105639 (2021).","journal-title":"Pharmacol Res"},{"issue":"2","key":"ref29","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.3390\/ijms25021199","type":"journal-article","article-title":"Cornelian cherry fruit extract lowers SREBP-1c and C\/EBP\u03b1 in liver and alters PPAR\/ LXR target genes in cholesterol-rich diet rabbit model","volume":"25","author":"Danielewski","year":"2024","unstructured":"Danielewski, M. et al. Cornelian cherry fruit extract lowers SREBP-1c and C\/EBP\u03b1 in liver and alters PPAR\/ LXR target genes in cholesterol-rich diet rabbit model. Int J Mol Sci. 25 (2), 1199 (2024).","journal-title":"Int J Mol Sci"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"106211","DOI":"10.1016\/j.jff.2024.106211","type":"journal-article","article-title":"Salvia miltiorrhiza bunge extract improves the Th17\/Treg imbalance and modulates gut microbiota of hypertensive rats induced by high-salt diet","volume":"117","author":"Qi","year":"2024","unstructured":"Qi, L. et al. Salvia miltiorrhiza bunge extract improves the Th17\/Treg imbalance and modulates gut microbiota of hypertensive rats induced by high-salt diet. J Funct Foods. 117, 106211 (2024).","journal-title":"J Funct Foods"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"9420002","DOI":"10.26599\/FMH.2024.9420002","type":"journal-article","article-title":"Cornus officinalis vinegar alters the gut microbiota, regulating lipid droplet changes in nonalcoholic fatty liver disease model mice","volume":"1","author":"Cao","year":"2024","unstructured":"Cao, L. et al. Cornus officinalis vinegar alters the gut microbiota, regulating lipid droplet changes in nonalcoholic fatty liver disease model mice. Food Med Homol. 1, 9420002 (2024).","journal-title":"Food Med Homol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1408778","DOI":"10.3389\/fnut.2024.1408778","type":"journal-article","article-title":"Microbiome-metabolome analysis insight into the effects of high-salt diet on hemorheological functions in SD rats","volume":"11","author":"Qi","year":"2024","unstructured":"Qi, L. et al. Microbiome-metabolome analysis insight into the effects of high-salt diet on hemorheological functions in SD rats. Front Nutr. 11, 1408778 (2024).","journal-title":"Front Nutr"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"133060","DOI":"10.1016\/j.ijbiomac.2024.133060","type":"journal-article","article-title":"Effects of three Huanglian-derived polysaccharides on the gut microbiome and fecal metabolome of high-fat diet\/streptozocin-induced type 2 diabetes mice","volume":"273","author":"Wang","year":"2024","unstructured":"Wang, J. et al. Effects of three Huanglian-derived polysaccharides on the gut microbiome and fecal metabolome of high-fat diet\/streptozocin-induced type 2 diabetes mice. Int J Biol Macromol. 273, 133060 (2024).","journal-title":"Int J Biol Macromol"},{"issue":"2","key":"ref34","first-page":"775","type":"journal-article","article-title":"Gut microbiota and atherosclerosis: Current status of traditional Chinese medicine intervention","volume":"40","author":"Gao","year":"2025","unstructured":"Gao, F. et al. Gut microbiota and atherosclerosis: Current status of traditional Chinese medicine intervention. China J Tradit Chin Med Pharm. 40 (2), 775-779 (2025).","journal-title":"China J Tradit Chin Med Pharm"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"118231","DOI":"10.1016\/j.lwt.2025.118231","type":"journal-article","article-title":"Identification and validation of core microbes for isoflavone conversion and flavor formation in fermented sojae semen praeparatum","volume":"229","author":"Hou","year":"2025","unstructured":"Hou, Y., et al. Identification and validation of core microbes for isoflavone conversion and flavor formation in fermented sojae semen praeparatum. LWT. 229, 118231 (2025).","journal-title":"LWT"},{"issue":"5","key":"ref36","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.3390\/nu12051330","type":"journal-article","article-title":"Trimethylamine N-oxide in relation to cardiometabolic health-Cause or effect","volume":"12","author":"Papandreou","year":"2020","unstructured":"Papandreou, C., Mor\u00e9, M., Bellamine, A. Trimethylamine N-oxide in relation to cardiometabolic health-Cause or effect? Nutrients. 12 (5), 1330 (2020).","journal-title":"Nutrients"},{"issue":"1","key":"ref37","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s13105-023-00984-y","type":"journal-article","article-title":"Trimethylamine N-oxide promotes oxidative stress and lipid accumulation in macrophage foam cells via the Nrf2\/ABCA1 pathway","volume":"80","author":"Luo","year":"2024","unstructured":"Luo, Z. et al. Trimethylamine N-oxide promotes oxidative stress and lipid accumulation in macrophage foam cells via the Nrf2\/ABCA1 pathway. J Physiol Biochem. 80 (1), 67-79 (2024).","journal-title":"J Physiol Biochem"},{"issue":"1","key":"ref38","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1161\/HYPERTENSIONAHA.120.14759","type":"journal-article","article-title":"Trimethylamine-N-oxide promotes age-related vascular oxidative stress and endothelial dysfunction in mice and humans","volume":"76","author":"Brunt","year":"2020","unstructured":"Brunt, V. E. et al. Trimethylamine-N-oxide promotes age-related vascular oxidative stress and endothelial dysfunction in mice and humans. Hypertension. 76 (1), 101-112 (2020).","journal-title":"Hypertension"},{"issue":"1","key":"ref39","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.cell.2016.02.011","type":"journal-article","article-title":"Gut microbial metabolite TMAO enhances platelet hyperreactivity and thrombosis risk","volume":"165","author":"Zhu","year":"2016","unstructured":"Zhu, W. et al. Gut microbial metabolite TMAO enhances platelet hyperreactivity and thrombosis risk. Cell. 165 (1), 111-124 (2016).","journal-title":"Cell"},{"issue":"3","key":"ref40","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.3390\/ijms24031940","type":"journal-article","article-title":"Gut microbiota-derived TMAO: A causal factor promoting atherosclerotic cardiovascular disease","volume":"24","author":"Canyelles","year":"2023","unstructured":"Canyelles, M. et al. Gut microbiota-derived TMAO: A causal factor promoting atherosclerotic cardiovascular disease? Int J Mol Sci. 24 (3), 1940 (2023).","journal-title":"Int J Mol Sci"},{"issue":"1","key":"ref41","first-page":"1","type":"journal-article","article-title":"Immunomodulatory potential of gut microbiome-derived short-chain fatty acids","volume":"66","author":"Ratajczak","year":"2019","unstructured":"Ratajczak, W. et al. Immunomodulatory potential of gut microbiome-derived short-chain fatty acids. Acta Biochim Pol. 66 (1), 1-12 (2019).","journal-title":"Acta Biochim Pol"},{"issue":"1","key":"ref42","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1152\/physrev.00041.2018","type":"journal-article","article-title":"Free fatty acid receptors in health and disease","volume":"100","author":"Kimura","year":"2020","unstructured":"Kimura, I. et al. Free fatty acid receptors in health and disease. Physiol Rev. 100 (1), 171-210 (2020).","journal-title":"Physiol Rev"},{"issue":"3","key":"ref43","first-page":"320","type":"journal-article","article-title":"Research progress on relationship between gut microbiota, short-chain fatty acids and coronary heart disease","volume":"37","author":"Zhang","year":"2025","unstructured":"Zhang, Y., Wang, D. J. Research progress on relationship between gut microbiota, short-chain fatty acids and coronary heart disease. Mod Pract Med. 37 (3), 320-323 (2025).","journal-title":"Mod Pract Med"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/med4.35","type":"journal-article","article-title":"Association of dietary patterns with cognitive function in older people: Results from the Chinese longitudinal healthy longevity survey","volume":"1","author":"Zheng","year":"2023","unstructured":"Zheng, H. et al. Association of dietary patterns with cognitive function in older people: Results from the Chinese longitudinal healthy longevity survey. Med Adv. 1, 246-259 (2023).","journal-title":"Med Adv"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.atherosclerosis.2020.08.028","type":"journal-article","article-title":"How strong is the evidence that gut microbiota composition can be influenced by lifestyle interventions in a cardio-protective way","volume":"311","author":"Gerdes","year":"2020","unstructured":"Gerdes, V. et al. How strong is the evidence that gut microbiota composition can be influenced by lifestyle interventions in a cardio-protective way? Atherosclerosis. 311, 124-142 (2020).","journal-title":"Atherosclerosis"},{"issue":"15","key":"ref46","doi-asserted-by":"crossref","first-page":"8074","DOI":"10.3390\/ijms22158074","type":"journal-article","article-title":"The role of gut microbiota on cholesterol metabolism in atherosclerosis","volume":"22","author":"Vourakis","year":"2021","unstructured":"Vourakis, M., Mayer, G., Rousseau, G. The role of gut microbiota on cholesterol metabolism in atherosclerosis. Int J Mol Sci. 22 (15), 8074 (2021).","journal-title":"Int J Mol Sci"},{"issue":"6","key":"ref47","doi-asserted-by":"crossref","first-page":"H1474","DOI":"10.1152\/ajpheart.00584.2019","type":"journal-article","article-title":"Small molecule inhibition of gut microbial choline trimethylamine lyase activity alters host cholesterol and bile acid metabolism","volume":"318","author":"Pathak","year":"2020","unstructured":"Pathak, P. et al. Small molecule inhibition of gut microbial choline trimethylamine lyase activity alters host cholesterol and bile acid metabolism. Am J Physiol Heart Circ Physiol. 318 (6), H1474-H1486 (2020).","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.atherosclerosis.2019.11.026","type":"journal-article","article-title":"Fasting serum total bile acid level is associated with coronary artery disease, myocardial infarction and severity of coronary lesions","volume":"292","author":"Li","year":"2020","unstructured":"Li, W. et al. Fasting serum total bile acid level is associated with coronary artery disease, myocardial infarction and severity of coronary lesions. Atherosclerosis. 292, 193-200 (2020).","journal-title":"Atherosclerosis"},{"issue":"3","key":"ref49","first-page":"569","type":"journal-article","article-title":"Role of bile acid metabolism in metabolic cardiovascular diseases","volume":"41","author":"Yang","year":"2025","unstructured":"Yang, W. Y., Zhang, X. Y., Yu, Y. Role of bile acid metabolism in metabolic cardiovascular diseases. Chin J Pathophysiol. 41 (3), 569-576 (2025).","journal-title":"Chin J Pathophysiol"},{"issue":"8","key":"ref50","first-page":"927","type":"journal-article","article-title":"Atherosclerosis: Process, indicators, risk factors and new hopes","volume":"5","author":"Rafieian-Kopaei","year":"2014","unstructured":"Rafieian-Kopaei, M. et al. Atherosclerosis: Process, indicators, risk factors and new hopes. Int J Prev Med. 5 (8), 927-946 (2014).","journal-title":"Int J Prev Med"},{"issue":"7","key":"ref51","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3390\/metabo11070453","type":"journal-article","article-title":"Plasma bile acid profile in patients with and without type 2 diabetes","volume":"11","author":"Mantovani","year":"2021","unstructured":"Mantovani, A. et al. Plasma bile acid profile in patients with and without type 2 diabetes. Metabolites. 11 (7), 453 (2021).","journal-title":"Metabolites"},{"issue":"4","key":"ref52","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s11154-019-09512-0","type":"journal-article","article-title":"Dietary lipids, gut microbiota and lipid metabolism","volume":"20","author":"Schoeler","year":"2019","unstructured":"Schoeler, M., Caesar, R. Dietary lipids, gut microbiota and lipid metabolism. Rev Endocr Metab Disord. 20 (4), 461-472 (2019).","journal-title":"Rev Endocr Metab Disord"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"106586","DOI":"10.1016\/j.phrs.2022.106586","type":"journal-article","article-title":"Gut microbiome and metabolites, the future direction of diagnosis and treatment of atherosclerosis","volume":"187","author":"Cao","year":"2023","unstructured":"Cao, H., Zhu, Y., Hu, G., Zheng, L. Gut microbiome and metabolites, the future direction of diagnosis and treatment of atherosclerosis? Pharmacol Res. 187, 106586 (2023).","journal-title":"Pharmacol Res"},{"issue":"5","key":"ref54","doi-asserted-by":"crossref","first-page":"e0127","DOI":"10.1097\/HC9.0000000000000127","type":"journal-article","article-title":"FXR and NASH: An avenue for tissue-specific regulation","volume":"7","author":"Henry","year":"2023","unstructured":"Henry, Z., Meadows, V., Guo, G. L. FXR and NASH: An avenue for tissue-specific regulation. Hepatol Commun. 7 (5), e0127 (2023).","journal-title":"Hepatol Commun"},{"issue":"6","key":"ref55","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/hep.32577","type":"journal-article","article-title":"Hepatocellular cystathionine \u03b3 lyase\/hydrogen sulfide attenuates nonalcoholic fatty liver disease by activating farnesoid X receptor","volume":"76","author":"Xu","year":"2022","unstructured":"Xu, W. et al. Hepatocellular cystathionine \u03b3 lyase\/hydrogen sulfide attenuates nonalcoholic fatty liver disease by activating farnesoid X receptor. Hepatology. 76 (6), 1794-1810 (2022).","journal-title":"Hepatology"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"154728","DOI":"10.1016\/j.metabol.2021.154728","type":"journal-article","article-title":"Glucagon-like peptide 1 analogue prevents cholesterol gallstone formation by modulating intestinal farnesoid X receptor activity","volume":"118","author":"Zhang","year":"2021","unstructured":"Zhang, Z. et al. Glucagon-like peptide 1 analogue prevents cholesterol gallstone formation by modulating intestinal farnesoid X receptor activity. Metabolism. 118, 154728 (2021).","journal-title":"Metabolism"},{"issue":"22","key":"ref57","doi-asserted-by":"crossref","first-page":"8732","DOI":"10.1074\/jbc.RA119.008360","type":"journal-article","article-title":"Phosphorylation of hepatic farnesoid X receptor by FGF19 signaling-activated Src maintains cholesterol levels and protects from atherosclerosis","volume":"294","author":"Byun","year":"2019","unstructured":"Byun, S. et al. Phosphorylation of hepatic farnesoid X receptor by FGF19 signaling-activated Src maintains cholesterol levels and protects from atherosclerosis. J Biol Chem. 294 (22), 8732-8744 (2019).","journal-title":"J Biol Chem"},{"issue":"1","key":"ref58","doi-asserted-by":"crossref","first-page":"6908","DOI":"10.1038\/s41467-023-42702-8","type":"journal-article","article-title":"Farnesoid X receptor activation by bile acids suppresses lipid peroxidation and ferroptosis","volume":"14","author":"Tschuck","year":"2023","unstructured":"Tschuck, J. et al. Farnesoid X receptor activation by bile acids suppresses lipid peroxidation and ferroptosis. Nat Commun. 14 (1), 6908 (2023).","journal-title":"Nat Commun"},{"issue":"8","key":"ref59","doi-asserted-by":"crossref","first-page":"e142865","DOI":"10.1172\/JCI142865","type":"journal-article","article-title":"Suppressing the intestinal farnesoid X receptor\/sphingomyelin phosphodiesterase 3 axis decreases atherosclerosis","volume":"131","author":"Wu","year":"2021","unstructured":"Wu, Q. et al. Suppressing the intestinal farnesoid X receptor\/sphingomyelin phosphodiesterase 3 axis decreases atherosclerosis. J Clin Invest. 131 (8), e142865 (2021).","journal-title":"J Clin Invest"},{"issue":"2","key":"ref60","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/2211-5463.13925","type":"journal-article","article-title":"FXR activation reduces macrophage foam cell formation and atherosclerotic plaque, possibly by downregulating hepatic lipase in macrophages","volume":"15","author":"Gu","year":"2025","unstructured":"Gu, Q., Liu, J., Shen, L. L. FXR activation reduces macrophage foam cell formation and atherosclerotic plaque, possibly by downregulating hepatic lipase in macrophages. FEBS Open Bio. 15 (2), 311-323 (2025).","journal-title":"FEBS Open Bio"},{"issue":"1","key":"ref61","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/1743-7075-9-75","type":"journal-article","article-title":"The impact of phospholipid transfer protein on lipoprotein metabolism","volume":"9","author":"Jiang","year":"2012","unstructured":"Jiang, X. C., Jin, W. J., Hussain, M. M. The impact of phospholipid transfer protein on lipoprotein metabolism. Nutr Metab. 9 (1), 75 (2012).","journal-title":"Nutr Metab"},{"issue":"15","key":"ref62","doi-asserted-by":"crossref","first-page":"5870","DOI":"10.3390\/molecules28155870","type":"journal-article","article-title":"Research progress of takeda G protein-coupled receptor 5 in metabolic syndrome","volume":"28","author":"Gou","year":"2023","unstructured":"Gou, X. et al. Research progress of takeda G protein-coupled receptor 5 in metabolic syndrome. Molecules. 28 (15), 5870 (2023).","journal-title":"Molecules"},{"issue":"6","key":"ref63","first-page":"711","type":"journal-article","article-title":"Research progress on role of TGR5 in cardiovascular diseases","volume":"49","author":"Yang","year":"2024","unstructured":"Yang, X. et al. Research progress on role of TGR5 in cardiovascular diseases. Med J Chin PLA. 49 (6), 711-717 (2024).","journal-title":"Med J Chin PLA"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"3523642","DOI":"10.1155\/2018\/3523642","type":"journal-article","article-title":"Involvement of M1 macrophage polarization in endosomal Toll-like receptors activated psoriatic inflammation","volume":"2018","author":"Lu","year":"2018","unstructured":"Lu, C. H. et al. Involvement of M1 macrophage polarization in endosomal Toll-like receptors activated psoriatic inflammation. Mediators Inflamm. 2018, 3523642 (2018).","journal-title":"Mediators Inflamm"},{"issue":"24","key":"ref65","doi-asserted-by":"crossref","first-page":"10343","DOI":"10.1021\/jm501052c","type":"journal-article","article-title":"G-protein-coupled bile acid receptor 1 agonists reduce proinflammatory cytokine production and stabilize alternative macrophage phenotype","volume":"57","author":"H\u00f6genauer","year":"2014","unstructured":"H\u00f6genauer, K. et al. G-protein-coupled bile acid receptor 1 agonists reduce proinflammatory cytokine production and stabilize alternative macrophage phenotype. J Med Chem. 57 (24), 10343-10354 (2014).","journal-title":"J Med Chem"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"609060","DOI":"10.3389\/fimmu.2020.609060","type":"journal-article","article-title":"TGR5 regulates macrophage inflammation in nonalcoholic steatohepatitis by modulating NLRP3 inflammasome activation","volume":"11","author":"Shi","year":"2021","unstructured":"Shi, Y. et al. TGR5 regulates macrophage inflammation in nonalcoholic steatohepatitis by modulating NLRP3 inflammasome activation. Front Immunol. 11, 609060 (2021).","journal-title":"Front Immunol"},{"issue":"7","key":"ref67","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1177\/02698811221089041","type":"journal-article","article-title":"Hyodeoxycholic acid inhibits LPS-induced microglia inflammatory responses through regulating TGR5\/AKT\/NF-\u03baB pathway","volume":"236","author":"Zhu","year":"2022","unstructured":"Zhu, H. et al. Hyodeoxycholic acid inhibits LPS-induced microglia inflammatory responses through regulating TGR5\/AKT\/NF-\u03baB pathway. Psychopharmacology. 236 (7), 849-859 (2022).","journal-title":"Psychopharmacology"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"118090","DOI":"10.1016\/j.ejmech.2025.118090","type":"journal-article","article-title":"Cyclin-dependent kinase 1 (CDK1) in cancers: from upstream regulation to downstream substrates and therapeutic inhibitors","volume":"299","author":"Chen","year":"2025","unstructured":"Chen, J., et al. Cyclin-dependent kinase 1 (CDK1) in cancers: from upstream regulation to downstream substrates and therapeutic inhibitors. Eur J Med Chem. 299, 118090 (2025).","journal-title":"Eur J Med Chem"},{"issue":"9","key":"ref69","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1194\/jlr.M087239","type":"journal-article","article-title":"Simultaneous inhibition of FXR and TGR5 exacerbates atherosclerotic formation","volume":"59","author":"Miyazaki-Anzai","year":"2018","unstructured":"Miyazaki-Anzai, S. et al. Simultaneous inhibition of FXR and TGR5 exacerbates atherosclerotic formation. J Lipid Res. 59 (9), 1709-1713 (2018).","journal-title":"J Lipid Res"},{"issue":"10","key":"ref70","first-page":"1086","type":"journal-article","article-title":"Research progress of bile acid reflux-induced intestinal metaplasia and gastric cancer","volume":"30","author":"Zhong","year":"2021","unstructured":"Zhong, Y. L., Li, G. Y., Huang, W. Research progress of bile acid reflux-induced intestinal metaplasia and gastric cancer. Chin J Gastroenterol Hepatol. 30 (10), 1086-1090 (2021).","journal-title":"Chin J Gastroenterol Hepatol"},{"issue":"218","key":"ref71","first-page":"e66923","type":"journal-article","article-title":"Mechanistic insights into salidroside's mitochondrial protection via AMPK\/Sirt1\/HIF-1\u03b1 pathway in hypoxic HT22 cells","author":"Wang","year":"2025","unstructured":"Wang, X., et al. Mechanistic insights into salidroside's mitochondrial protection via AMPK\/Sirt1\/HIF-1\u03b1 pathway in hypoxic HT22 cells. J Vis Exp. 218, e66923 (2025).","journal-title":"J Vis Exp"},{"issue":"1","key":"ref72","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s12933-022-01531-7","type":"journal-article","article-title":"Correlation between triglyceride-to-HDL cholesterol ratio and other unconventional lipid parameters with prediabetes and type 2 diabetes in coronary heart disease","volume":"21","author":"Yang","year":"2022","unstructured":"Yang, T. et al. Correlation between triglyceride-to-HDL cholesterol ratio and other unconventional lipid parameters with prediabetes and type 2 diabetes in coronary heart disease. Cardiovasc Diabetol. 21 (1), 93 (2022).","journal-title":"Cardiovasc Diabetol"},{"issue":"7","key":"ref73","first-page":"607","type":"journal-article","article-title":"Statins increase low molecular weight apolipoprotein(a) phenotype and lipoprotein(a) levels in Uygur CHD patients","volume":"21","author":"Ji","year":"2023","unstructured":"Ji, H. Y. et al. Statins increase low molecular weight apolipoprotein(a) phenotype and lipoprotein(a) levels in Uygur CHD patients. Chin J Cardiovasc Res. 21 (7), 607-612 (2023).","journal-title":"Chin J Cardiovasc Res"},{"issue":"129","key":"ref74","first-page":"e56596","type":"journal-article","article-title":"Differential effects of lipid-lowering drugs in modulating morphology of cholesterol particles","author":"Madasamy","year":"2017","unstructured":"Madasamy, S. et al. Differential effects of lipid-lowering drugs in modulating morphology of cholesterol particles. J Vis Exp. 129, e56596 (2017).","journal-title":"J Vis Exp"},{"issue":"9","key":"ref75","first-page":"240","type":"journal-article","article-title":"Can Chinese ACS patients tolerate high-intensity statin therapy based on clinical cases","volume":"30","author":"Cai","year":"2018","unstructured":"Cai, R. Y. Can Chinese ACS patients tolerate high-intensity statin therapy based on clinical cases. Strait Pharm J. 30 (9), 240-243 (2018).","journal-title":"Strait Pharm J"},{"issue":"5","key":"ref76","first-page":"132","type":"journal-article","article-title":"How to use statins for hyperlipidemia patients","author":"Shi","year":"2025","unstructured":"Shi, H. Y. How to use statins for hyperlipidemia patients. Sci Life. (5), 132-133 (2025).","journal-title":"Sci Life"},{"issue":"3","key":"ref77","first-page":"213","type":"journal-article","article-title":"Chinese expert recommendations on primary-level lipid management technology and quality control","volume":"40","year":"2025","unstructured":"National Committee of Cardiovascular Metabolic Medicine. Chinese expert recommendations on primary-level lipid management technology and quality control. Chin Circ J. 40 (3), 213-218 (2025).","journal-title":"Chin Circ J"},{"issue":"31","key":"ref78","first-page":"35","type":"journal-article","article-title":"Research progress in diagnosis and treatment of dyslipidemia","volume":"14","author":"Chen","year":"2024","unstructured":"Chen, X. Y., Chen, J. L., Shen, C. B. Research progress in diagnosis and treatment of dyslipidemia. J Front Med. 14 (31), 35-37 (2024).","journal-title":"J Front Med"},{"key":"ref79","doi-asserted-by":"crossref","first-page":"107380","DOI":"10.1016\/j.clineuro.2022.107380","type":"journal-article","article-title":"Risk factors and their correlation with severity of cerebral microbleed in acute large artery atherosclerotic cerebral infarction patients","volume":"221","author":"Chen","year":"2022","unstructured":"Chen, Y., Ye, M. Risk factors and their correlation with severity of cerebral microbleed in acute large artery atherosclerotic cerebral infarction patients. Clin Neurol Neurosurg. 221, 107380 (2022).","journal-title":"Clin Neurol Neurosurg"},{"key":"ref80","first-page":"105","type":"journal-article","article-title":"Long-term management of coronary heart disease: Drug and lifestyle coordination","volume":"14","author":"Liu","year":"2025","unstructured":"Liu, G. Q., Li, H. H. Long-term management of coronary heart disease: Drug and lifestyle coordination. Health Must-Read. 14, 105 (2025).","journal-title":"Health Must-Read"},{"key":"ref81","first-page":"80","type":"journal-article","article-title":"Elderly heart health: Scientific use of antiplatelet drugs","volume":"4","author":"Zheng","year":"2025","unstructured":"Zheng, Z. H., Li, W. Y. Elderly heart health: Scientific use of antiplatelet drugs. Med People. 4, 80-81 (2025).","journal-title":"Med People"},{"key":"ref82","doi-asserted-by":"crossref","first-page":"n48","DOI":"10.1136\/bmj.n48","type":"journal-article","article-title":"Effect of redundant clinical trials from mainland China evaluating statins in coronary artery disease","volume":"372","author":"Jia","year":"2021","unstructured":"Jia, Y. et al. Effect of redundant clinical trials from mainland China evaluating statins in coronary artery disease. BMJ. 372, n48 (2021).","journal-title":"BMJ"},{"issue":"3","key":"ref83","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0092-8674(00)80213-5","type":"journal-article","article-title":"The SREBP pathway: Regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor","volume":"89","author":"Brown","year":"1997","unstructured":"Brown, M. S., Goldstein, J. L. The SREBP pathway: Regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell. 89 (3), 331-340 (1997).","journal-title":"Cell"},{"issue":"4","key":"ref84","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/ATVBAHA.108.179564","type":"journal-article","article-title":"The LDL receptor","volume":"29","author":"Goldstein","year":"2009","unstructured":"Goldstein, J. L., Brown, M. S. The LDL receptor. Arterioscler Thromb Vasc Biol. 29 (4), 431-438 (2009).","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"ref85","first-page":"37","type":"journal-article","article-title":"Research progress in lipid-lowering therapy for coronary heart disease","volume":"45","author":"Hu","year":"2025","unstructured":"Hu, Y. C., Liu, Y. H., Zou, Q. S., Xie, D. Y. Research progress in lipid-lowering therapy for coronary heart disease. J Gannan Med Univ. 45 (1), 37-44 (2025).","journal-title":"J Gannan Med Univ"},{"issue":"12","key":"ref86","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1001\/jamainternmed.2021.5714","type":"journal-article","article-title":"Association of statin therapy initiation with diabetes progression","volume":"181","author":"Mansi","year":"2021","unstructured":"Mansi, I. et al. Association of statin therapy initiation with diabetes progression. JAMA Intern Med. 181 (12), 1562-1574 (2021).","journal-title":"JAMA Intern Med"},{"issue":"6","key":"ref87","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1517\/14740338.2015.1039980","type":"journal-article","article-title":"Statin intolerance - an attempt at a unified definition","volume":"14","author":"Banach","year":"2015","unstructured":"Banach, M. et al. Statin intolerance - an attempt at a unified definition. Expert Opin Drug Saf. 14 (6), 935-955 (2015).","journal-title":"Expert Opin Drug Saf"},{"issue":"2","key":"ref88","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.12677\/ACM.2023.132216","type":"journal-article","article-title":"Lipid-lowering efficacy of combined lipid-lowering therapy and its effect on glucose metabolism","volume":"13","author":"Xia","year":"2023","unstructured":"Xia, Y., Li, G. Q. Lipid-lowering efficacy of combined lipid-lowering therapy and its effect on glucose metabolism. Adv Clin Med. 13 (2), 1567-1573 (2023).","journal-title":"Adv Clin Med"},{"issue":"4","key":"ref89","first-page":"280","type":"journal-article","article-title":"Chinese expert consensus on lipid management in very high-risk atherosclerotic cardiovascular disease patients","volume":"48","year":"2020","unstructured":"Chinese Society of Cardiology, Atherosclerosis and Coronary Heart Disease Working Group, Editorial Board of Chinese Journal of Cardiology. Chinese expert consensus on lipid management in very high-risk atherosclerotic cardiovascular disease patients. Chin J Cardiol. 48 (4), 280-286 (2020).","journal-title":"Chin J Cardiol"},{"key":"ref90","first-page":"31","type":"journal-article","article-title":"Cholesterol-lowering drugs may damage liver and kidney","volume":"1","author":"L\u00fc","year":"2025","unstructured":"L\u00fc, X. X. Cholesterol-lowering drugs may damage liver and kidney. Healthy Life. 1, 31-33 (2025).","journal-title":"Healthy Life"},{"issue":"2","key":"ref91","first-page":"411","type":"journal-article","article-title":"Effect of different doses of atorvastatin on vascular endothelial function in atherosclerosis","volume":"42","author":"Yang","year":"2021","unstructured":"Yang, W. Effect of different doses of atorvastatin on vascular endothelial function in atherosclerosis. Jilin MedJ. 42 (2), 411-413 (2021).","journal-title":"Jilin MedJ"},{"key":"ref92","first-page":"87","type":"journal-article","article-title":"Trends in functional food development from cardiovascular disease prevention perspective","volume":"4","author":"Chen","year":"2025","unstructured":"Chen, J. J., Wu, S. Y. Trends in functional food development from cardiovascular disease prevention perspective. China Food. 4, 87-89 (2025).","journal-title":"China Food"},{"issue":"11","key":"ref93","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s11883-020-00883-3","type":"journal-article","article-title":"Targeting inflammation to reduce residual cardiovascular risk","volume":"22","author":"Ajala","year":"2020","unstructured":"Ajala, O. N., Everett, B. M. Targeting inflammation to reduce residual cardiovascular risk. Curr Atheroscler Rep. 22 (11), 66 (2020).","journal-title":"Curr Atheroscler Rep"},{"issue":"8","key":"ref94","first-page":"21","type":"journal-article","article-title":"Effect of fenofibrate combined with simvastatin on hyperlipidemia","volume":"35","author":"Li","year":"2023","unstructured":"Li, X. P., Nie, D. P., Li, H. P. Effect of fenofibrate combined with simvastatin on hyperlipidemia. Chin J Conval Med. 35 (8), 21-23 (2023).","journal-title":"Chin J Conval Med"},{"issue":"1","key":"ref95","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s12944-020-01415-3","type":"journal-article","article-title":"Emerging insights into the relationship between hyperlipidemia and the risk of diabetic retinopathy","volume":"19","author":"Chou","year":"2020","unstructured":"Chou, Y. et al. Emerging insights into the relationship between hyperlipidemia and the risk of diabetic retinopathy. Lipids Health Dis. 19 (1), 241 (2020).","journal-title":"Lipids Health Dis"},{"issue":"9","key":"ref96","first-page":"24","type":"journal-article","article-title":"Blood-eye barrier and systemic drug delivery for ocular diseases","volume":"20","author":"Yu","year":"2022","unstructured":"Yu, K. F., Cao, W. X., Xu, B., Shi, W. Z., Zhao, Z. G. Blood-eye barrier and systemic drug delivery for ocular diseases. Clin Med J. 20 (9), 24-27 (2022).","journal-title":"Clin Med J"},{"key":"ref97","doi-asserted-by":"crossref","first-page":"11863","DOI":"10.1038\/s41598-017-11070-x","type":"journal-article","article-title":"Atorvastatin but not pravastatin impairs mitochondrial function in human pancreatic islets","volume":"7","author":"Urbano","year":"2017","unstructured":"Urbano, F. et al. Atorvastatin but not pravastatin impairs mitochondrial function in human pancreatic islets. Sci Rep. 7, 11863 (2017).","journal-title":"Sci Rep"},{"issue":"15","key":"ref98","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1161\/CIRCULATIONAHA.122.061620","type":"journal-article","article-title":"Long-term evolocumab in established atherosclerotic cardiovascular disease","volume":"146","author":"O'Donoghue","year":"2022","unstructured":"O'Donoghue, M. et al. Long-term evolocumab in established atherosclerotic cardiovascular disease. Circulation. 146 (15), 1109-1119 (2022).","journal-title":"Circulation"},{"issue":"11","key":"ref99","doi-asserted-by":"crossref","first-page":"4226","DOI":"10.1210\/jc.2017-01250","type":"journal-article","article-title":"Cold-induced brown adipose tissue activity alters plasma fatty acids and improves glucose metabolism","volume":"102","author":"Iwen","year":"2017","unstructured":"Iwen, K. et al. Cold-induced brown adipose tissue activity alters plasma fatty acids and improves glucose metabolism. J Clin Endocrinol Metab. 102 (11), 4226-4234 (2017).","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"ref100","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.cmet.2018.11.017","type":"journal-article","article-title":"Inhibition of mevalonate pathway prevents adipocyte browning","volume":"29","author":"Balaz","year":"2019","unstructured":"Balaz, M. et al. Inhibition of mevalonate pathway prevents adipocyte browning. Cell Metab. 29 (4), 901-916 (2019).","journal-title":"Cell Metab"},{"issue":"18","key":"ref101","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1089\/ars.2016.6631","type":"journal-article","article-title":"Cross-talk between PCSK9 and damaged mtDNA in vascular smooth muscle cells","volume":"25","author":"Ding","year":"2016","unstructured":"Ding, Z. et al. Cross-talk between PCSK9 and damaged mtDNA in vascular smooth muscle cells. Antioxid Redox Signal. 25 (18), 997-1008 (2016).","journal-title":"Antioxid Redox Signal"},{"issue":"9","key":"ref102","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1093\/cvr\/cvaa254","type":"journal-article","article-title":"PCSK9 and LRP5 in macrophage lipid internalization and inflammation","volume":"117","author":"Badimon","year":"2021","unstructured":"Badimon, L. et al. PCSK9 and LRP5 in macrophage lipid internalization and inflammation. Cardiovasc Res. 117 (9), 2054-2068 (2021).","journal-title":"Cardiovasc Res"},{"issue":"10","key":"ref103","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1161\/CIRCRESAHA.118.311227","type":"journal-article","article-title":"PCSK9: From basic science discoveries to clinical trials","volume":"122","author":"Shapiro","year":"2018","unstructured":"Shapiro, M. D., Tavori, H., Fazio, S. PCSK9: From basic science discoveries to clinical trials. Circ Res. 122 (10), 1420-1438 (2018).","journal-title":"Circ Res"},{"key":"ref104","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/med4.70009","type":"journal-article","article-title":"Associations between lipids and lipid-lowering drug target genes and osteomyelitis: A Mendelian randomization analysis","volume":"3","author":"Zhou","year":"2025","unstructured":"Zhou, Z. et al. Associations between lipids and lipid-lowering drug target genes and osteomyelitis: A Mendelian randomization analysis. Med Adv. 3, 80-87 (2025).","journal-title":"Med Adv"},{"issue":"4","key":"ref105","doi-asserted-by":"crossref","first-page":"517","DOI":"10.4093\/dmj.2022.0198","type":"journal-article","article-title":"novel lipid-lowering agents for reducing cardiovascular risk","volume":"46","author":"Kim","year":"2022","unstructured":"Kim, K., Ginsberg, H. N., Choi, S. H. New, novel lipid-lowering agents for reducing cardiovascular risk. Diabetes Metab J. 46 (4), 517-532 (2022).","journal-title":"Diabetes Metab J"},{"issue":"7","key":"ref106","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1001\/jamacardio.2019.0886","type":"journal-article","article-title":"Effect of evolocumab on total cardiovascular events in cardiovascular disease","volume":"4","author":"Murphy","year":"2019","unstructured":"Murphy, S. A. et al. Effect of evolocumab on total cardiovascular events in cardiovascular disease. JAMA Cardiol. 4 (7), 613-619 (2019).","journal-title":"JAMA Cardiol"},{"issue":"18","key":"ref107","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","type":"journal-article","article-title":"Evolocumab and clinical outcomes in cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","unstructured":"Sabatine, M. S. et al. Evolocumab and clinical outcomes in cardiovascular disease. N Engl J Med. 376 (18), 1713-1722 (2017).","journal-title":"N Engl J Med"},{"issue":"1","key":"ref108","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1080\/14712598.2020.1677604","type":"journal-article","article-title":"PCSK9 inhibitors and cardiovascular outcomes","volume":"20","author":"Steffens","year":"2020","unstructured":"Steffens, D. et al. PCSK9 inhibitors and cardiovascular outcomes. Expert Opin Biol Ther. 20 (1), 35-47 (2020).","journal-title":"Expert Opin Biol Ther"},{"issue":"3","key":"ref109","first-page":"311","type":"journal-article","article-title":"Safety of PCSK9 inhibitors when reducing LDL-C to very low levels","volume":"44","author":"L\u00fc","year":"2025","unstructured":"L\u00fc, R. X., Gu, W. Safety of PCSK9 inhibitors when reducing LDL-C to very low levels. J Cardiovasc Pulm Dis. 44 (3), 311-315 (2025).","journal-title":"J Cardiovasc Pulm Dis"},{"key":"ref110","doi-asserted-by":"crossref","first-page":"632","DOI":"10.3390\/genes14030632","type":"journal-article","article-title":"Interplay between microRNAs, serum proprotein convertase Subtilisin\/Kexin Type 9 (PCSK9), and lipid parameters in patients with very high lipoprotein(a) treated with PCSK9 inhibitors","volume":"14","author":"Levstek","year":"2023","unstructured":"Levstek, T., et al. Interplay between microRNAs, serum proprotein convertase Subtilisin\/Kexin Type 9 (PCSK9), and lipid parameters in patients with very high lipoprotein(a) treated with PCSK9 inhibitors. Genes. 14, 632 (2023).","journal-title":"Genes"},{"issue":"5","key":"ref111","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jacl.2022.06.009","type":"journal-article","article-title":"Small interfering ribonucleic acid for cholesterol lowering - inclisiran","volume":"16","author":"Soffer","year":"2022","unstructured":"Soffer, D., Stoekenbroek, R., Plakogiannis, R. Small interfering ribonucleic acid for cholesterol lowering - inclisiran. J Clin Lipidol. 16 (5), 574-582 (2022).","journal-title":"J Clin Lipidol"},{"issue":"186","key":"ref112","first-page":"e64588","type":"journal-article","article-title":"Research methodologies in vascular disease","author":"Fittipaldi","year":"2022","unstructured":"Fittipaldi, S., Vasuri, F. Research methodologies in vascular disease. J Vis Exp. 186, e64588 (2022).","journal-title":"J Vis Exp"},{"issue":"5","key":"ref113","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jacc.2020.05.070","type":"journal-article","article-title":"Targeting RNA with antisense oligonucleotides in dyslipidemias","volume":"76","author":"Katzmann","year":"2020","unstructured":"Katzmann, J. L. et al. Targeting RNA with antisense oligonucleotides in dyslipidemias. J Am Coll Cardiol. 76 (5), 563-579 (2020).","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"ref114","doi-asserted-by":"crossref","first-page":"375","DOI":"10.31083\/j.rcm2311375","type":"journal-article","article-title":"Inclisiran: A new pharmacological approach for hypercholesterolemia","volume":"23","author":"Di Fusco","year":"2022","unstructured":"Di Fusco, S. A. et al. Inclisiran: A new pharmacological approach for hypercholesterolemia. Rev Cardiovasc Med. 23 (11), 375 (2022).","journal-title":"Rev Cardiovasc Med"},{"issue":"15","key":"ref115","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","type":"journal-article","article-title":"et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol","volume":"376","author":"Ray","year":"2017","unstructured":"Ray, K. K. et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med. 376 (15), 1430-1440 (2017).","journal-title":"N Engl J Med"},{"key":"ref116","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2147\/VHRM.S338424","type":"journal-article","article-title":"Inclisiran: A new strategy for LDL-C lowering and ASCVD prevention","volume":"19","author":"Albosta","year":"2023","unstructured":"Albosta, M. S. et al. Inclisiran: A new strategy for LDL-C lowering and ASCVD prevention. Vasc Health Risk Manag. 19, 421-431 (2023).","journal-title":"Vasc Health Risk Manag"},{"key":"ref117","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.atherosclerosis.2023.04.012","type":"journal-article","article-title":"Responses to lipoprotein(a) consensus statement","volume":"374","author":"Kronenberg","year":"2023","unstructured":"Kronenberg, F. et al. Responses to lipoprotein(a) consensus statement. Atherosclerosis. 374, 107-120 (2023).","journal-title":"Atherosclerosis"},{"issue":"6","key":"ref118","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.jacasi.2022.08.015","type":"journal-article","article-title":"Lipoprotein(a) and cardiovascular disease in Chinese population","volume":"2","author":"Li","year":"2022","unstructured":"Li, J. J. et al. Lipoprotein(a) and cardiovascular disease in Chinese population. JACC Asia. 2 (6), 653-665 (2022).","journal-title":"JACC Asia"},{"issue":"39","key":"ref119","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","type":"journal-article","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis","volume":"43","author":"Kronenberg","year":"2022","unstructured":"Kronenberg, F. et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis. Eur Heart J. 43 (39), 3925-3946 (2022).","journal-title":"Eur Heart J"},{"issue":"1","key":"ref120","first-page":"e48","type":"journal-article","article-title":"Lipoprotein(a): A causal risk factor for ASCVD","volume":"42","author":"Reyes-Soffer","year":"2022","unstructured":"Reyes-Soffer, G. et al. Lipoprotein(a): A causal risk factor for ASCVD. Arterioscler Thromb Vasc Biol. 42 (1), e48-e60 (2022).","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"ref121","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/eurjpc\/zwab171","type":"journal-article","article-title":"Statin therapy and lipoprotein(a) levels","volume":"29","author":"de Boer","year":"2022","unstructured":"de Boer, L. M. et al. Statin therapy and lipoprotein(a) levels. Eur J Prev Cardiol. 29 (5), 779-792 (2022).","journal-title":"Eur J Prev Cardiol"},{"issue":"11","key":"ref122","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1001\/jama.2023.16503","type":"journal-article","article-title":"Muvalaplin, an oral inhibitor of lipoprotein(a) formation","volume":"330","author":"Nicholls","year":"2023","unstructured":"Nicholls, S. J. et al. Muvalaplin, an oral inhibitor of lipoprotein(a) formation. JAMA. 330 (11), 1042-1053 (2023).","journal-title":"JAMA"},{"issue":"1","key":"ref123","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/13543784.2024.2302592","type":"journal-article","article-title":"Potential of muvalaplin as a lipoprotein(a) inhibitor","volume":"33","author":"Hooper","year":"2024","unstructured":"Hooper, A. J., Fernando, P. M. S., Burnett, J. R. Potential of muvalaplin as a lipoprotein(a) inhibitor. Expert Opin Investig Drugs. 33 (1), 5-7 (2024).","journal-title":"Expert Opin Investig Drugs"},{"key":"ref124","type":"book","volume-title":"Triglyceride Lowering Drugs","author":"Feingold","year":"2024","unstructured":"Feingold, K. R. Triglyceride Lowering Drugs. Endotext, South Dartmouth, MA (2024)."},{"key":"ref125","type":"book","volume-title":"Risk of fasting and non-fasting hypertriglyceridemia in CVD","author":"Geier","year":"2022","unstructured":"Geier, R. R., Tannock, L. R. Risk of fasting and non-fasting hypertriglyceridemia in CVD. Endotext, South Dartmouth, MA (2022)."},{"issue":"1","key":"ref126","first-page":"15","type":"journal-article","article-title":"Chinese guidelines for dyslipidemia in adults (2016 revision)","volume":"16","year":"2017","unstructured":"Joint Committee on Revision of Chinese Guidelines for Dyslipidemia. Chinese guidelines for dyslipidemia in adults (2016 revision). Chin J Gen Pract. 16 (1), 15-35 (2017).","journal-title":"Chin J Gen Pract"},{"issue":"3","key":"ref127","first-page":"221","type":"journal-article","article-title":"Chinese guidelines on lipid management (2023)","volume":"51","year":"2023","unstructured":"China Cholesterol Education Program. Chinese guidelines on lipid management (2023). Chin J Cardiol. 51 (3), 221-255 (2023).","journal-title":"Chin J Cardiol"},{"issue":"9493","key":"ref128","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","type":"journal-article","article-title":"Efficacy and safety of cholesterol-lowering treatment","volume":"366","author":"Baigent","year":"2005","unstructured":"Baigent, C. et al. Efficacy and safety of cholesterol-lowering treatment. Lancet. 366 (9493), 1267-1278 (2005).","journal-title":"Lancet"},{"issue":"14","key":"ref129","first-page":"1408","type":"journal-article","article-title":"Transiently achieved very low LDL-C levels by statin and alirocumab reduce cardiovascular risk","volume":"44","author":"Schwartz","year":"2023","unstructured":"Schwartz, G. G. et al. Transiently achieved very low LDL-C levels by statin and alirocumab reduce cardiovascular risk. Eur Heart J. 44 (14), 1408-1417 (2023).","journal-title":"Eur Heart J"},{"issue":"3","key":"ref130","doi-asserted-by":"crossref","first-page":"e351","DOI":"10.1016\/j.jacl.2024.01.006","type":"journal-article","article-title":"Lipid Association of India consensus statement IV","volume":"18","author":"Puri","year":"2024","unstructured":"Puri, R. et al. Lipid Association of India consensus statement IV. J Clin Lipidol. 18 (3), e351-e373 (2024).","journal-title":"J Clin Lipidol"},{"issue":"24","key":"ref131","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","type":"journal-article","article-title":"AHA\/ACC cholesterol management guideline","volume":"73","author":"Grundy","year":"2019","unstructured":"Grundy, S. M. et al. 2018 AHA\/ACC cholesterol management guideline. J Am Coll Cardiol. 73 (24), e285-e350 (2019).","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"ref132","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","type":"journal-article","article-title":"ESC\/EAS guidelines for dyslipidaemias","volume":"41","author":"Mach","year":"2020","unstructured":"Mach, F. et al. 2019 ESC\/EAS guidelines for dyslipidaemias. Eur Heart J. 41 (1), 111-188 (2020).","journal-title":"Eur Heart J"},{"issue":"3","key":"ref133","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3390\/jcdd10030127","type":"journal-article","article-title":"Impact of blood lipids on arterial stiffness","volume":"10","author":"Baba","year":"2023","unstructured":"Baba, M. et al. Impact of blood lipids on arterial stiffness. J Cardiovasc Dev Dis. 10 (3), 127 (2023).","journal-title":"J Cardiovasc Dev Dis"},{"key":"ref134","doi-asserted-by":"crossref","first-page":"119136","DOI":"10.1016\/j.atherosclerosis.2025.119136","type":"journal-article","article-title":"Genetic association of lipids and lipid-lowering targets with vascular calcification","volume":"403","author":"Zhang","year":"2025","unstructured":"Zhang, P. et al. Genetic association of lipids and lipid-lowering targets with vascular calcification. Atherosclerosis. 403, 119136 (2025).","journal-title":"Atherosclerosis"},{"key":"ref135","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ejim.2023.10.013","type":"journal-article","article-title":"Residual cardiovascular risk: When to treat","volume":"120","author":"Gomez-Delgado","year":"2024","unstructured":"Gomez-Delgado, F. et al. Residual cardiovascular risk: When to treat? Eur J Intern Med. 120, 17-24 (2024).","journal-title":"Eur J Intern Med"},{"issue":"24","key":"ref136","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1016\/j.jacc.2021.04.059","type":"journal-article","article-title":"Triglycerides and residual atherosclerotic risk","volume":"77","author":"Raposeiras-Roubin","year":"2021","unstructured":"Raposeiras-Roubin, S. et al. Triglycerides and residual atherosclerotic risk. J Am Coll Cardiol. 77 (24), 3031-3041 (2021).","journal-title":"J Am Coll Cardiol"},{"key":"ref137","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1093\/eurheartj\/ehae258","type":"journal-article","article-title":"Discordance among apoB, non-high-density lipoprotein cholesterol, and triglycerides: implications for cardiovascular prevention","volume":"45","author":"Sniderman","year":"2024","unstructured":"Sniderman, A. D.et al. Discordance among apoB, non-high-density lipoprotein cholesterol, and triglycerides: implications for cardiovascular prevention. Eur Heart J. 45, 2410-2418 (2024).","journal-title":"Eur Heart J"},{"key":"ref138","doi-asserted-by":"crossref","first-page":"e025858","DOI":"10.1161\/JAHA.122.025858","type":"journal-article","article-title":"Physiological bases for the superiority of apolipoprotein B over low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol as a marker of cardiovascular risk","volume":"11","author":"Glavinovic","year":"2022","unstructured":"Glavinovic, T.et al. Physiological bases for the superiority of apolipoprotein B over low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol as a marker of cardiovascular risk. J Am Heart Assoc. 11, e025858 (2022).","journal-title":"J Am Heart Assoc"},{"key":"ref139","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1042\/BCJ20240037","type":"journal-article","article-title":"Lipoprotein(a) and cardiovascular disease","volume":"481","author":"Boffa","year":"2024","unstructured":"Boffa, M. B. and Koschinsky, M. L. Lipoprotein(a) and cardiovascular disease. Biochem J. 481, 1277-1296 (2024).","journal-title":"Biochem J"},{"key":"ref140","doi-asserted-by":"crossref","first-page":"486","DOI":"10.3390\/nu16040486","type":"journal-article","article-title":"Non-interventional weight changes are associated with alterations in lipid profiles and in the triglyceride-to-HDL cholesterol ratio","volume":"16","author":"Weinstein","year":"2024","unstructured":"Weinstein, S., et al. Non-interventional weight changes are associated with alterations in lipid profiles and in the triglyceride-to-HDL cholesterol ratio. Nutrients. 16, 486 (2024).","journal-title":"Nutrients"},{"issue":"5","key":"ref141","doi-asserted-by":"crossref","first-page":"929","DOI":"10.3390\/diagnostics13050929","type":"journal-article","article-title":"TG\/HDL-C ratio as risk marker for metabolic syndrome and CVD","volume":"13","author":"Kosmas","year":"2023","unstructured":"Kosmas, C. E. et al. TG\/HDL-C ratio as risk marker for metabolic syndrome and CVD. Diagnostics. 13 (5), 929 (2023).","journal-title":"Diagnostics"},{"key":"ref142","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3389\/fcvm.2020.00088","type":"journal-article","article-title":"Evolving approach to residual cardiovascular risk management","volume":"7","author":"Dhindsa","year":"2020","unstructured":"Dhindsa, D. S. et al. Evolving approach to residual cardiovascular risk management. Front Cardiovasc Med. 7, 88 (2020).","journal-title":"Front Cardiovasc Med"},{"issue":"2","key":"ref143","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s10072-022-06472-3","type":"journal-article","article-title":"Non-traditional lipid parameters predict carotid plaque vulnerability in stroke","volume":"44","author":"Zhao","year":"2023","unstructured":"Zhao, Z. et al. Non-traditional lipid parameters predict carotid plaque vulnerability in stroke. Neurol Sci. 44 (2), 835-843 (2023).","journal-title":"Neurol Sci"},{"issue":"4","key":"ref144","first-page":"6115","type":"journal-article","article-title":"Research progress on TG\/HDL-C and cardiovascular diseases","volume":"13","author":"G\u00fczainuer","year":"2023","unstructured":"G\u00fczainuer, R., Peng, P. Research progress on TG\/HDL-C and cardiovascular diseases. Adv Clin Med. 13 (4), 6115-6120 (2023).","journal-title":"Adv Clin Med"},{"issue":"10","key":"ref145","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1016\/j.numecd.2020.05.009","type":"journal-article","article-title":"Triglyceride to high-density lipoprotein cholesterol ratio and risk of atherosclerotic cardiovascular disease in a Chinese population","volume":"30","author":"Zhou","year":"2020","unstructured":"Zhou, L. et al. Triglyceride to high-density lipoprotein cholesterol ratio and risk of atherosclerotic cardiovascular disease in a Chinese population. Nutr Metab Cardiovasc Dis. 30 (10), 1706-1713 (2020).","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"3","key":"ref146","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.hlc.2019.03.019","type":"journal-article","article-title":"Elevated TG\/HDL ratio predicts long-term mortality in high-risk patients","volume":"29","author":"Sultani","year":"2020","unstructured":"Sultani, R. et al. Elevated TG\/HDL ratio predicts long-term mortality in high-risk patients. Heart Lung Circ. 29 (3), 414-421 (2020).","journal-title":"Heart Lung Circ"},{"key":"ref147","doi-asserted-by":"crossref","first-page":"2253478","DOI":"10.1155\/2022\/2253478","type":"journal-article","article-title":"Atherogenesis, transcytosis, and the transmural cholesterol flux: A critical review","volume":"2022","author":"Goldberg","year":"2022","unstructured":"Goldberg, D. and Khatib, S. Atherogenesis, transcytosis, and the transmural cholesterol flux: A critical review. Oxid Med Cell Longev. 2022, 2253478 (2022).","journal-title":"Oxid Med Cell Longev"},{"key":"ref148","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.17305\/bjbms.2022.7142","type":"journal-article","article-title":"Associations of non-HDL-C and triglyceride\/HDL-C ratio with coronary plaque burden and plaque characteristics in young adults","volume":"22","author":"Akin","year":"2022","unstructured":"Akin, F. et al. Associations of non-HDL-C and triglyceride\/HDL-C ratio with coronary plaque burden and plaque characteristics in young adults. Bosn J Basic Med Sci. 22, 1025-1032 (2022).","journal-title":"Bosn J Basic Med Sci"},{"key":"ref149","doi-asserted-by":"crossref","first-page":"4740","DOI":"10.1038\/s41598-023-31772-9","type":"journal-article","article-title":"Development and clinical validation of Swaasa AI platform for screening and prioritization of pulmonary TB","volume":"13","author":"Yellapu","year":"2023","unstructured":"Yellapu, G. D. et al. Development and clinical validation of Swaasa AI platform for screening and prioritization of pulmonary TB. Sci Rep. 13, 4740 (2023).","journal-title":"Sci Rep"},{"key":"ref150","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.3390\/bioengineering10121396","type":"journal-article","article-title":"Discovery Viewer (DV): Web-based medical AI model development platform and deployment hub","volume":"10","author":"Fauveau","year":"2023","unstructured":"Fauveau, V. et al. Discovery Viewer (DV): Web-based medical AI model development platform and deployment hub. Bioengineering. 10, 1396 (2023).","journal-title":"Bioengineering"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/med4.70008","type":"journal-article","article-title":"Effectiveness of remote glucose monitoring versus conventional care in diabetes management: A systematic review and meta-analysis","volume":"3","author":"Odutola","year":"2025","unstructured":"Odutola, P. O.et al. Effectiveness of remote glucose monitoring versus conventional care in diabetes management: A systematic review and meta-analysis. Med Adv. 3, 28-36 (2025).","journal-title":"Med Adv"},{"key":"ref152","type":"journal-article","article-title":"PRMT5 encourages cell migration and metastasis of tongue squamous cell carcinoma through methylating \u0394Np63\u03b1","author":"Fan","year":"2025","unstructured":"Fan, S., et al. PRMT5 encourages cell migration and metastasis of tongue squamous cell carcinoma through methylating \u0394Np63\u03b1. Cell Death Differ. (2025).","journal-title":"Cell Death Differ"}],"container-title":["Journal of Visualized Experiments"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/app.jove.com\/t\/69357\/precision-management-dyslipidemia-atherosclerosis-mechanisms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:26:00Z","timestamp":1792592760000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jove.com\/t\/69357\/precision-management-dyslipidemia-atherosclerosis-mechanisms"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,3]]},"references-count":152,"journal-issue":{"issue":"224","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.3791\/69357","relation":{},"ISSN":["1940-087X"],"issn-type":[{"value":"1940-087X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,3]]}}}